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Research on the molecular mechanisms involved in Huntington’s disease, a monogenic disorder with a complex
phenotype including motor, behaviour, and cognitive impairments, is advancing at a rapid path. Knowledge on
several of the multimodal pathways has now lead to the establishment of rational strategies to prepare trials of
several compounds in affected people. Furthermore, improved understanding of the phenotype and on ways of
assessing it, as well as the process of developing biomarkers, allows setting the frame for such studies. In this brief
review, the present status of some of these aspects is examined.Review
Huntington’s disease is a complex autosomal-dominant
disorder with a variable phenotype comprising motor, cog-
nitive and psychiatric symptoms and signs [1,2]. The mu-
tation is fully penetrant and leads to death after a
relentless progressive course of impairment with a gradual
loss of function until death after 15–25 years. HD is
a monogenetic degenerative disorder, which can be
diagnosed well in advance of any symptom, opening up
opportunities for a disease-modifying treatment long be-
fore symptom onset, which typically occur around 40
years old. This disorder may therefore be considered as a
paradigm for the development of novel, neuroprotective
treatments. At this time, no such treatment is available
[3], but the dramatic increase in our understanding of the
molecular pathways involved in the pathogenesis of this
disorder, and the availability of several animal models to
perform preclinical testing of emerging therapeutic strat-
egies, may nurture some hope for the future. The develop-
ment of symptomatic treatment still plays an important
role and there is a lack of good evidence from clinical
trials. The boundaries between a HD specific treatment
based upon knowledge of the complex pathogenic
mechanisms involved at the molecular level and a causal
treatment aimed at reversing some of these eventsCorrespondence: Jean-marc.burgunder@dkf.unibe.ch
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reproduction in any medium, provided the ormay finally not be so sharp. In this review, some aspects of
the complex molecular pathogenesis, for which our
understanding has advanced so far, that clinical trials may
be contemplated, will be examined. The status of clinical
development of strategies based upon these mechanisms
will be presented.
Huntington’s Disease: a complex phenotype
The typical presentation of HD is the development of sub-
tle cognitive and behavioural changes with involuntary,
hyperkinetic, choreatic movements at around 40 years old.
In the case of a dominant phenotype with a similar dis-
order in the family, a high accuracy diagnosis can be
made, at least in those countries in Europe and America,
where HD prevalence is relativly high. A number of other
abnormal movements may be present, including dystonia,
eye movement disturbances, bradykinesia, rigidity, gait
and balance problems, myoclonus, and spasticity. Further-
more, they may have different presentations between
young and old disease onset and evolve during the differ-
ent stages of the disorder. Likewise, neuropsychological
disturbances may be quite subtle at onset and evolve grad-
ually over time, selectively affecting some aspects of cogni-
tion more than others. Difficulties in time assessment
speed of cognitive processes and emotion detection may
be detected early in the course of the disorder. They
are typically followed by executive dysfunction, impair-
ment in communication, memory and symptom unaware-
ness [4]. Depressed mood, anxiety, irritability and apathy,
are among the most frequently observed psychiatric signs
[5], followed by obsessive compulsive symptoms andd. This is an Open Access article distributed under the terms of the Creative
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disorder. It is important to note, that there are substantial
variations in this presentation, and some very early cases
[6] have a developmental brain disorder, while late cases
may be undistinguishable from senile chorea. This vari-
ation already stresses the importance of tailored treatment,
as it is the case for symptomatic management [7].
Scales have been introduced to reliably assess the differ-
ent aspects of the phenotype. The most frequent one is
the United Huntington’s Disease (UHDRS) rating scale
[8]. It comprises motor, cognitive, behavioural, and func-
tional scales and has the advantage to offer precise
instructions and training opportunities. The UHDRS may
be complemented with additional specific instruments in
order to assess particular aspects of the presentation.
When disease-modifying treatment are examined, two
aspects need particular attention, the age at onset and the
choice of biomarkers to assess progression. Age at onset is
often taken as the time, when motor symptoms and signs
occur. This is easily understandable, since these can be
quite accurately seen and measured. However, subtle cog-
nitive and psychiatric changes may already impair func-
tion, and might represent targets for treatment aiming at
delaying disease onset. For this reason, Registry, the large
observational study, run by the European Huntington’s
Disease Network (EHDN), uses a form capturing the his-
tory of motor, behaviour (depression, irritability, apathy,
aggressive behaviour, obsession, psychosis) and cognitive
impairment in an open and unbiased way.
Furthermore, our increased understanding of the
phenotype and the course of the disorders, including the
development of biomarkers, allows the preparation of
improved strategies in implementing therapeutic trials.
The choice of biomarkers for protective studies will have
to be tailored to which aspect of the neurodegenerative
disease process and of the consecutive neuroplastic
adaptation needs to be approached. An intensive, 3 years
study of a cohort of HD gene carriers in a premanifest
and in an early stage of the disease has recently been
published [9-11]. A test battery including clinical cogni-
tive, quantitative motor, oculomotor and neuropsychi-
atric measures as well as imaging methods was used
to search for appropriate markers, which would demon-
strate a change over the period of investigation. In the
cross-sectional report comparing the three groups
at baseline, differences in brain-imaging data, some neuro-
physiological motor and oculomotor tasks assessments, as
well as cognitive and neuropsychiatric scales were found
[9]. However, only a smaller number of these variables
were subject to change during the longitudinal observa-
tion, stressing the importance of test validation in a pro-
spective way. These data overall allow the suggestion that
MRI assessments, including whole-brain atrophy, ven-
tricular expansion, caudate atrophy, putamen atrophy, andwhite-matter atrophy, are valuable biomarkers both in the
presymptomatic and in the early manifest stages. In the
first, cognitive test may be added, for example the symbol
digit modality test, the Stroop word reading and the emo-
tion recognition test [11]. A follow-up protocol to these
important studies in now in place and additional data are
expected in the near future. They will inform the protocol
of future clinical trials aimed at disease modification. Other
studies have examined other clinical, cognitive, and
neuroimaging assessments, and several biochemical
parameters have also been suggested [12], but there is a
need of replication and assessment in a longitudinal way
before they can be seen as established for future clinical
trials.
The genetic background of HD
HD is due to an elongation of a CAG triplet repeat in
exon 1 of the huntingtin (IT15) gene located on chromo-
some 4p16.3 [13]. Alleles with less than 27 CAG are nor-
mal and those with more than 39 fully penetrant for the
disease phenotype, with an inverse correlation between
the number of repeats and the age at onset. Repeats be-
tween 36 and 39 are incompletely penetrant and those be-
tween 27 and 35 are not associated with disease but with a
higher risk for the next generation [14].
The CAG repeat is translated in a glutamine stretch of
the huntingtin protein, which leads to the accumulation of
an abnormal protein. Huntingtin itself has a number of
functions in the cell, specifically in striatal spiny neurons,
which all can be disturbed by the mutated protein [15].
These include modulation of gene transcription, impair-
ment of protein trafficking and autophagy, disturbed
energy metabolism and mitochondrial function, modula-
tion of dynamic axonal transport mechanisms due to
impaired microtubular dynamics, endocytic and vesicular
trafficking changes at the presynaptic sites and modulation
of postsynaptic signalling mechanisms. All these molecu-
lar events may theoretically be modulated by targeted
pharmacological interventions. Some are more advanced
along preclinical development paths and they are briefly
reviewed here.
Gene therapy
Strategies to inhibit the expression of the protein by the
larger allele have been developed. They include different
types of RNA molecules and antisense oligonucleotides
(ASO) targeting the mutated transcript. Both strategies
lead to the inhibition of HTT expression. This decrease in
HTT expression improves the symptoms and prolongs
survival in HD mouse models [16,17]. Problems, however,
may occur in decreasing huntingtin overall expression, in-
cluding the normal allele, since some cellular functions
modulated by this protein may be impaired. In order to
decrease expression only of the larger allele, strategies
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with the triplet repeat elongation to specifically target the
mutated transcript are being explored [18].
Small interfering RNA (siRNA) may decrease mutated
HTT RNA with a consecutive decrease in mutated protein
and have been found to improve phenotype in animal
models [19]. It is possible to design siRNA targeted at the
mutant allele in a selective way allowing a normal expres-
sion of wild type huntingtin[20]. Mesenchymal stromal
cells have been develop to express siRNA and tested with
success in a number of animal models and their potential
to treat HD is promising [21]. A trial using a construct
with siRNA in healthy volunteers inoculated with respira-
tory syncytial virus has demonstrated its antiviral activity,
thus establishing a proof of concept for such an approach
[22]. Of course the challenge of delivering siRNA in the
brain is higher than in the readily accessible upper airways
and the issue of long-term safety remains a concern, al-
though the stereotactic intraparenchymal delivery of
siRNA packaged into a modified andenovirus has been
found safe for 6 months in primates [23]. In treated
animals, HTT mRNA levels fell by 28% compared with
control animals receiving unspecific RNA, protein levels
also significantly decreased. A programme had been
announced to start phase I studies with continuous
intracerebral application of an RNAi therapeutic by using
a pump system [24], however this has been retracted
again, showing the difficult path of development for such
strategies. Chemical modifications of siRNA may improve
stability with retaining high silencing capability and tissue
spread after local application [25].
Ansisense oligonucleotide (ASO) may be prepared to tar-
get specifically HTT mRNA [26], inducing their degrad-
ation by RNase activity. They can be modified to make
them resistant to exonuclease cleavage, which improve their
stability. After injection in the mammalian brain, they de-
crease HTT mRNA levels in the striatum without any mor-
phological change. There a time lag in the restoration of
mutant HTT mRNA levels there after transient inhibition
[27]. A clinical trial to examine safety, tolerability and activ-
ity of an ASO treatment is presently undergoing in amyo-
trophic lateral sclerosis caused by SOD1 gene mutations
(http://clinicaltrials.gov/ identifier: NCT01041222).
Challenges concerning HTT gene silencing remain,
they include the delivery process and target volume
choice, timing of treatment along the course of the dis-
ease, as well as long-term effects and side effects, but
these strategies offer promise for a real impact in chan-
ging the course of the disorder in a meaningful way.
Targeting the mutated protein
The CAG repeat expansion is translated in a glutamine
stretch of the huntingtin molecule, a protein, which
undergoes a number of posttranslational modifications,including acetylation, phosphorylation, SUMOylation,
ubiquitination, palmytoilation and proteolytic cleavage.
This has lead to the suggestion, that modification of
these posttranslational processes might modulate the
levels of abnormal huntingtin [28].
The polyphenol (2)-epigallocatechin-3-gallate (EGCG),
a component of green tee, inhibits the aggregation of
mutated huntingtin in vitro [29], the starting of a phase
II trial in HD has been reported (http://clinicaltrials.gov,
identifyer: NCT01357681).
Sirtuin 1 is involved in the postranslational modifica-
tion of Huntingtin and acts by deacetylation of the pro-
tein. Sirtuin 1 inhibition has been postulated to lead to
increase clearance of mutated huntingtin (http://www.
paddingtonproject.eu/). A randomised, double-blind
placebo-controlle phase iB pharmacodynamic study has
now been run in HD patients [30].
Another way would be to develop strategies using
chaperones to improve clearance of the abnormal pro-
tein. Indeed removal of the abnormal protein, for ex-
ample by over expression of a human heat shock protein
in HSJ1a in mice bearing the HD mutation, lead to a sig-
nificant decrease in insoluble HTT and size of inclusions
[31]. Another way to clear the abnormal protein in order
to decrease its toxic effects would be to engineer anti-
body specifically reacting with mutated huntingtin.
Single-chain, single-domain antibodies targeted to intra-
cellular huntingtin with expanded glutamine track have
been used in several animal models with improvement
of the phenotype [32].
Improving mitochondrial function
Mitochondrial function is impaired in HD as demonstrated
by a decrease in the function of several complexes along
the electron transport chain [33,34], decrease in mitochon-
drial density, and morphological alteration in brains from
HD patients [35]. Mutated huntingtin impairs mitochon-
drial function by a number of different mechanisms, includ-
ing permeability transition pore modulation, decrease of
PGCα expression, stimulation of glutamate receptor by
increased depolarisation, mitochondrial fractionation, and
impaired respiratory chain function [36]. Several thera-
peutic approaches have been followed based on this
background.
Coenzyme Q, a lipid-soluble molecule with antioxi-
dant, and membrane-stabilizing properties, is involved in
oxidative phosphorylation and represent a potential
neuroprotective compound suggested to improve mito-
chondrial function. Coenzyme Q has been tested in HD,
however, only a trend in improvement was measured. A
follow-up trial has tested higher doses, and they appear
to be safe [37]. There are currently two studies,
sponsored by the National Institutes of Health in the
USA further exploring the effect of Coenzyme Q10 in
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randomized double blind controlled trial to test the toler-
ability of high doses (600 to 2400 mg per day) in pre-
manifest participants with CAG triplet elongation (http://
clinicaltrials.gov, identifier: NCT00920699). The other is a
long-term randomized double blind study to examine
whether coenzyme Q10 is effective in slowing HD symp-
tom worsening. Almost 50 sites are involved for this on-
going, 5 years-long trial, for which enrolment has been
closed (http://clinicaltrials.gov, identifier: NCT00608881).
Creatine is a high-energy phosphate donor, which has
been tested in animal models of HD. In patients with
HD 8g/day of creatine was well-tolerated and improved
a biochemical indicator of oxidative injury [38]. Another,
multicentre study with a long-term perspective of 3
years to examine the effect of high-dose creatine on pro-
gression of functional decline in adults with early clinical
signs of HD is still on-going (http://clinicaltrials.gov,
accession number NCT00712426).
Cell repair strategies
Several strategies have been explored to replace
degenerated neurons in order to restore networks in the
striatum. In earlier pilot studies, bilateral transplantation
of embryonic tissue in the caudate of HD patients has lead
to a short benefit in some patients [39]. A long-term
multicentric study on the efficacy of intracerebral grafting
is now ongoing in Europe and results are expected
after final completion scheduled in Mai 2013 (http://
clinicaltrials.gov, identification number: NCT00190450).
One short-coming is the fact, that neuronal transplants
undergo a disease-related degeneration similar to the host
[40]. Immune response with rejection of the graft may also
be an important limiting factor [41]. Ethical issues, the
poor availability and inhomogeneity of donor tissues rep-
resent other problems linked with the use of fresh embry-
onic tissue. For these reasons, other strategies for cell
replacement in HD have been followed.
Human embryonic stem cells have been developed
and shown to improve clinical phenotype in animal
models of HD, however, their use in human may be
hampered by immunological and trophic mechanisms
[42]. Somatic cells may be reprogrammed into pluripo-
tent stem cells, which would provide a source of cells
for replacement therapy. In a recent landmark study, the
mutation could be corrected in pluripotent stem cells
derived fibroblasts from patients with HD by the re-
placement of the expanded CAG repeat with a normal
repeat. These cells developed into neurons in vitro and
in vivo, which had a normalised molecular phenotype
[43]. Such a strategy may open new venues in cell ther-
apy for the treatment of HD patients in later stages of
the disorder, when other means of treatment are not
possible anymore.Finally, cells may also be reengineered to produce
trophic factors [42]. For example astrocytes may be
induced to producing BDNF, and have demonstrated
some encouraging success in animal studies [44]. Novel
technologies allow the preparation of mesenchymal stro-
mal cells to treat a number of disorders and phase I-III
studies are underway, for example to treat chronic liver
disease [45] or multiple sclerosis [46].
The place of symptomatic therapies
The implementation even of the most promising strategies
aimed at modifying the disease process, in order to
delay onset and slow progression will take years at least.
There is therefore the need to improve on symptomatic
treatments, which can be classified in two overlapping cat-
egories. A specific approach is based on knowledge of the
disease molecular mechanisms or on studies examining an
aspect of the phenotype in a HD. A non-specific approach,
which has been mostly used in the past, is based on the
phenotypical characterisation and generalisation from other
disorders, in which aspects of the phenotype are shared.
Unfortunately, only few high quality clinical trials have been
performed specifically for treatment of symptoms in HD
patients [47]. We have performed a survey of the treatment
of HD chorea in different regions and found important
differences, pointing at the lack of consensus [48]. Needs of
the patient, including stigma, physical injury, gait instability,
work interference, and disturbed sleep were indications to
start treatment of chorea. However, the choice of drug var-
ied substantially.
Tetrabenazine is the only drug approved by the USA
food and drug administration for the treatment of chorea
in HD [49]. The major mechanism of tetrabenazine action
is the inhibition of a vesicular monoamine transporter
(VMAT). Brain VMAT2 is active in cytoplasmatic dopa-
mine transport and storage in synaptic vesicles. In a short-
term randomised control trial involving 84 patients over
12 weeks, Tetrabenazine, at adjusted doses up to 100 mg
per day, was shown to decrease the UHDRS chorea
subscore by 5 points (placebo 1.5) [50]. There was also an
improvement in the global clinical impression. After dis-
continuation of the drug, chorea worsened again. In a sec-
ond, smaller randomized controlled trial of tetrabenazine
withdrawal worsening of 5 points was found [51]. One re-
cent study has been devoted to the treatment of cognitive
impairment specifically in HD.
In a double blind assessment did treatment with
latrepirdine for 6 months not improve cognition or func-
tion relative to placebo [52]. Deep brain stimulation has
also been suggested on the basis of an understanding of
basal ganglia dysfunction in HD to treat chorea [53].
There is certainly a need for future trials on drugs and
other non-pharmacological treatment based on improved
knowledge of the pathophysiology of the disorder.
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As shown already be the few examples cited above, the
field of translational research in HD is moving at a fast
speed and hope for breakthrough in several areas can
now be nurtured in a cautious way. At the present time,
several avenues are quite promising, they include gene si-
lencing strategies to decrease expression of the transcript
with elongated triplet repeat part, Huntingtin modifying
compounds, cell strategies to provide trophic factors, and
molecules targeting mitochondria. Several other pathways
are expected to emerge further as well. In any case,
the complexity of the pathophysiological mechanisms
involved in HD will be reflected by a complex set of ther-
apies with synergistic properties, and it is not to be
expected that a single treatment would be sufficient.
The recognition that HD, due to the fact that the cause
is precisely known and can be recognised long before
onset, may be a paradigm for disease modifying treatment
in neurodegenerative disorders in general, has fostered
interest of researchers, pharmaceutical companies and
sponsors alike. The involvement of the clinical care com-
munity and, of course, of the people affected themselves,
together with above partners, is being highly instrumental
for the progress in this field. This has been well exempli-
fied by the work of the Huntington Study Group, the
EHDN, and will certainly be the case as well by newly
established networks like the Latin American HD
Network, and the Chinese Huntington’s Disease Network.
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